Dr. Pierre-Michel Bringer
  • Doctor of Pharmacy / Pharm.D

  • Strategic and operational expertise in Investor / Analyst relations, and in financial communication

  • Development of training courses for Corporate Finance skills and for financial communication

  • Management of Cross-functional multicultural teams

  • English / French

    – – – – –

  • Why PM. BRINGER CONSULTING  –  more

Dr. Pierre-Michel Bringer
  • Doctor of Pharmacy / Pharm.D
  • Strategic and operational expertise in Investor / Analyst relations, and in financial communication
  • Development of training courses for Corporate Finance skills and for financial communication
  • Management of Cross-functional multicultural teams
  • English / French
    – – – – –
  • Why PM. BRINGER CONSULTING more

 Why PM. Bringer Consulting

Over 35 years in the Pharmaceutical industry, in many different roles: investor relations, communication, business development, strategic planning, marketing & sales …

… I met and worked with fascinating professionals, inspired by the unknown, passionate about preparing the future, professionals ready to reinvent medicine and the world, while helping society to get ready for it with conviction but with humility

… I also met brilliant individuals but incapable of structuring their communication and that of their teams, as soon as they left their professional comfort zone or their area of ​​expertise

Based on these observations, reinforced by numerous recent discussions with investors, analysts and directors, I decided at this stage of my career to create PM.Bringer Consulting with:

  1. the ambition to help biopharmaceutical executives to improve the quality and reliability, and therefore the efficiency, of their financial communication

     

  2. the idea of sharing my experiences with biotechs and students, especially in Pharmacy
slogan

 Experiences

Since April 2021

Member of the Corporate Finance commission
FRANCE BIOTECH

Creation and animation of an Investor Relations working group 

Since 2020

President and founder
PM. BRINGER CONSULTING

Strategic financial communication consultant / investor relations 

  • helping Biotech executives improve the efficiency of their communication with the capital market, maximizing its impact, while remaining compliant

2007 – 2020

Investor Relations Officer
Novartis – Basel

Relations with equity analysts and investors 

  • establish and maintain professional relationships with sell-side and buy-side analysts and with investors, help them further deepen their understanding of Novartis data and Equity Story, answer their questions
  • organize and conduct international roadshows, alone or with Executives
  • present at bank conferences in plenary session or group meetings, alone or with Executives

Public speaking training for new spokespersons

  • over 40 executives trained and prepared for public speaking in the context of IR activities, mostly Executive Committee members, and Heads of Franchises and Development Units, or large geographies

      • specificities of financial communication in Pharma
      • market actors, and practical implications
      • legal context, DOs and DON’Ts
      • support development of key messages specific to each speaker in their respective role
      • rehearsal of questions and answers (Q&A) and of the Elevator pitch
      • live coaching on the road for the first event(s)

Training of new “IR contributors” to the IR function, its purpose and needs

  • help IR Contributors (strategic assistant, project team leaders, franchise, communication …) understand the challenges and specific needs of the IR function (Q&A, slides, investors meetings …) at Novartis
  • facilitate the integration of our new IR managers

Financial communication tools

  • analyse and prepare external communication of partnership and M&A projects with biotechs (eg Alcon, AveXis, The Medicines Company, etc.)
  • contribute to the preparation of press releases, Q&A, quarterly slide decks or newsflow related
  • participate in the definition, organization and preparation of Capital Market Days

Scientific expertise

  • acquire and develop IR required scientific and clinical knowledge with the Development and Medical teams, adapt it for Financial Communication purposes, and train the entire IR team on it
  • attend key global medical congresses in relation to our franchises, engage with KOLs and presenters and obtain their perspectives on our and competitors data

1985 – 2007

2004 – 2007 Individual shareholders relations 
Aventis, now Sanofi – Strasbourg / Paris

2002 – 2004 Financial function development / High potential training 
Aventis, now Sanofi – Francfort / Strasbourg

2000 – 2003 Strategic Business plan
Aventis, now Sanofi – Francfort

1999 – 2000 Integration Officer
HMR, now Sanofi – Bridgewater, USA / Francfort

More

Education

1978 – 1983

University of Pharmacy, René Descartes

1983 Doctor of Pharmacy / Pharm.D. (Diplôme d’Etat de Docteur en Pharmacie)

  • Thesis « Logiciel d’orientation aux tests statistiques »

1982 – 1983 Founder and 1st President of the student association ALEE Paris

 Experiences

Since April 2021

Member of the Corporate Finance commission

Creation and animation of an Investor Relations working group

Since 2020

President and founder

Strategic financial communication consultant / investor relations 

  • help Biotech executives improve the efficiency of their communication with the capital market, maximizing its impact, while remaining compliant

2007 – 2020

Investor Relations Officer

Relations with equity analysts and investors 

  • establish and maintain professional relationships with sell-side and buy-side analysts and with investors, help them further deepen their understanding of Novartis data and Equity Story, answer their questions
  • organize and conduct international roadshows, alone or with Executives
  • present at bank conferences in plenary session or group meetings, alone or with Executives

Public speaking training for new spokespersons

  • over 40 trained and prepared for public speaking in the IR context, mostly of the Executive Committee members, and Heads of franchises or large geographies
    • specificities of financial communication in Pharma
    • market actors, and practical implications
    • legal context, DOs and DON’Ts
    • support development of key messages specific to each speaker in their respective role
    • rehearsal of questions and answers (Q&A) and of the Elevator pitch
    • live coaching on the road for the first event(s)

Training of new “IR contributors” to the IR function, its purpose and needs

  • help IR Contributors (strategic assistant, project team leaders, franchise, communication …) understand the challenges and specific needs of the IR function (Q&A, slides, investors meetings …) at Novartis
  • facilitate the integration of our newly appointed IR managers

Financial communication tools

  • analyse Business Development and M&A projects (eg Alcon, AveXis, The Medicines Company, etc.), develop IR communication plan and prepare communication material (conference calls, etc.)
  • contribute to the preparation of press releases, Q&A, quarterly slide decks or newsflow related
  • participate in the definition, organization and preparation of Capital Market Days

Scientific expertise

  • acquire and develop required scientific and clinical expertise with the Development and Medical teams, adapt it for Financial Communication purposes, and train the entire IR team on it
  • attend key global medical congresses in relation to our franchises, engage with KOLs and presenters and obtain their perspectives on our and competitors data

1985 – 2007

2004 – 2007 Individual shareholders relations 
Aventis, now Sanofi – Strasbourg / Paris

2002 – 2004 Financial function development / High potential training 
Aventis, now Sanofi – Francfort / Strasbourg

2000 – 2003 Strategic Business plan
Aventis, now Sanofi – Francfort

1999 – 2000 Integration Officer
HMR, now Sanofi – Bridgewater, USA / Francfort

More

Education

1979 – 1983

University of Pharmacy, René Descartes

1983 Doctor of Pharmacy / Pharm.D. (Diplôme d’Etat de Docteur en Pharmacie)

  • Thesis « Logiciel d’orientation aux tests statistiques »

1982 – 1983 Founder and 1st President of the student association ALEE Paris